APW
ATNM icon

Allied Private Wealth’s Actinium Pharmaceuticals ATNM Stock Holding History

Allied Private Wealth’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$232 Buy
+240
New +$277 ﹤0.01% 865

Other funds holding ATNM

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CFM
Compass Financial Management Tampa, Florida $829M AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Allied Private Wealth's ATNM Position: Q2 2026 in Review

Allied Private Wealth opened a new position in Actinium Pharmaceuticals (ATNM) in Q2 2026: 240 shares worth $232. The stake represents ﹤0.01% of the portfolio and ranks #865 among its holdings.

47 funds tracked by Wall St. Rank hold ATNM as of Q2 2026.

  • Allied Private Wealth held 240 shares of Actinium Pharmaceuticals worth $232 as of Q2 2026.
  • Actinium Pharmaceuticals was a new Allied Private Wealth position in Q2 2026.
  • Actinium Pharmaceuticals made up ﹤0.01% of Allied Private Wealth's portfolio in Q2 2026, its #865 holding.
  • 47 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q2 2026.

Based on Allied Private Wealth's 13F filing for Q2 2026, filed 9 Jul 2026.